Drug Approval | July 09, 2024
Olverembatinib approved for commercialization in Macau China
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Subscribe To Our Newsletter & Stay Updated
